DGX Quote, Financials, Valuation and Earnings

Exact Sciences has a net margin of 8.3% compared to Quest Diagnostics's net margin of -14.32%. Quest Diagnostics's return on equity of 13.14% beat Exact Sciences's return on equity of -35.57%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 4.16%. On the other hand Exact Sciences has an analysts' consensus of $68.81 which suggests that it could grow by 29.16%. Given that Exact Sciences has higher upside potential than Quest Diagnostics, analysts believe Exact Sciences is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Exact Sciences has a beta of 0.920, suggesting its less volatile than the S&P 500 by 7.968%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.73%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Exact Sciences quarterly revenues of $706.8M. Quest Diagnostics's net income of $220M is higher than Exact Sciences's net income of -$101.2M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.32x while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.97x versus 3.49x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of 8.3% compared to Quest Diagnostics's net margin of 16.94%. Quest Diagnostics's return on equity of 13.14% beat Illumina's return on equity of -35.09%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 4.16%. On the other hand Illumina has an analysts' consensus of $115.55 which suggests that it could grow by 51.34%. Given that Illumina has higher upside potential than Quest Diagnostics, analysts believe Illumina is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Illumina has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.945%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.73%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Illumina quarterly revenues of $1.1B. Quest Diagnostics's net income of $220M is higher than Illumina's net income of $187M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.32x while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.97x versus 2.78x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 8.3% compared to Quest Diagnostics's net margin of 6.36%. Quest Diagnostics's return on equity of 13.14% beat Labcorp Holdings's return on equity of 9.01%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 4.16%. On the other hand Labcorp Holdings has an analysts' consensus of $272.40 which suggests that it could grow by 10.78%. Given that Labcorp Holdings has higher upside potential than Quest Diagnostics, analysts believe Labcorp Holdings is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.43%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.73%. Labcorp Holdings offers a yield of 1.17% to investors and pays a quarterly dividend of $0.72 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Quest Diagnostics's net income of $220M is higher than Labcorp Holdings's net income of $212.8M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.32x while Labcorp Holdings's PE ratio is 28.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.97x versus 1.57x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Mettler-Toledo International has a net margin of 8.3% compared to Quest Diagnostics's net margin of 18.51%. Quest Diagnostics's return on equity of 13.14% beat Mettler-Toledo International's return on equity of --.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 4.16%. On the other hand Mettler-Toledo International has an analysts' consensus of $1,260.38 which suggests that it could grow by 16.22%. Given that Mettler-Toledo International has higher upside potential than Quest Diagnostics, analysts believe Mettler-Toledo International is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Mettler-Toledo International has a beta of 1.396, suggesting its more volatile than the S&P 500 by 39.573%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.73%. Mettler-Toledo International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Mettler-Toledo International pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Mettler-Toledo International quarterly revenues of $883.7M. Quest Diagnostics's net income of $220M is higher than Mettler-Toledo International's net income of $163.6M. Notably, Quest Diagnostics's price-to-earnings ratio is 22.32x while Mettler-Toledo International's PE ratio is 27.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.97x versus 5.99x for Mettler-Toledo International. Usually stocks with elevated PS ratios are considered overvalued.